Clinical Data AAIC 2026: Lilly keeps door open for maintenance Kisunla after amyloid clearance BioSpaceEli Lilly's anti-amyloid Alzheimer's drug is designed to be stopped after patients drop below a certain amyloid level in the brain.NeuroscienceRead full story pharminent July 15, 2026 (Last updated: July 17, 2026) BioSpace Eli Lilly’s anti-amyloid Alzheimer’s drug is designed to be stopped after patients drop below a certain amyloid level in the brain. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Celcuity gets FDA nod for first-in-class breast cancer drugNext: AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
